Literature DB >> 12359110

Advances in the management of Guillain-Barré syndrome.

Deborah M Green1.   

Abstract

Guillain-Barré syndrome (GBS) is the most common cause of acute paralysis, yet the pathogenesis has still not been fully elucidated and specific evidence-based consensus management guidelines have not been developed. This paper reviews the research of the past year dedicated to determining the pathogenesis of GBS, optimizing current management, and searching for more efficacious treatment alternatives. Several recent studies have investigated whether there are any particular factors that might predict the course of illness and, thereby, dictate the optimal treatment. Proposed evidence-based guidelines for elective intubation, admission to the intensive care unit, and overall management of GBS are summarized. Therapeutic plasma exchange and intravenous immunoglobulin are both treatments that have been shown to have a beneficial effect on the course of GBS. Various modifications of plasmapheresis, as well as other alternative therapies, are currently being investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359110     DOI: 10.1007/s11910-002-0043-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  44 in total

1.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups.

Authors:  M Koga; N Yuki; K Hirata
Journal:  Acta Neurol Scand       Date:  2001-05       Impact factor: 3.209

Review 3.  Axonal Guillain-Barré syndrome: a critical review.

Authors:  D Chowdhury; A Arora
Journal:  Acta Neurol Scand       Date:  2001-05       Impact factor: 3.209

4.  Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody.

Authors:  S Kuwabara; M Mori; K Ogawara; T Hattori; S Oda; M Koga; N Yuki
Journal:  Muscle Nerve       Date:  2001-01       Impact factor: 3.217

5.  Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.

Authors:  R Van Koningsveld; P A Van Doorn; P I Schmitz; C W Ang; F G Van der Meché
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

Review 6.  Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis.

Authors:  S Nagpal; T Benstead; K Shumak; G Rock; M Brown; D R Anderson
Journal:  J Clin Apher       Date:  1999       Impact factor: 2.821

7.  Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange.

Authors:  P O Osterman; J Fagius; J Säfwenberg; B Wikström
Journal:  Acta Neurol Scand       Date:  1988-04       Impact factor: 3.209

8.  Limited relapse in Guillain-Barré syndrome after plasma exchange.

Authors:  A E Ropper; J W Albert; R Addison
Journal:  Arch Neurol       Date:  1988-03

9.  Infections and course of disease in mild forms of Guillain-Barré syndrome.

Authors:  R Van Koningsveld; P I M Schmitz; C W Ang; J Groen; A D M E Osterhaus; F G A Van der Meché; P A Van Doorn
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

10.  Treatment of Guillain-Barré syndrome with high-dose gammaglobulin.

Authors:  R P Kleyweg; F G van der Meché; J Meulstee
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

View more
  2 in total

Review 1.  Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.

Authors:  Luis Querol; Cinta Lleixà
Journal:  Neurotherapeutics       Date:  2021-09-21       Impact factor: 7.620

2.  Autoantibody screening in Guillain-Barré syndrome.

Authors:  Cinta Lleixà; Lorena Martín-Aguilar; Elba Pascual-Goñi; Teresa Franco; Marta Caballero; Noemí de Luna; Eduard Gallardo; Xavier Suárez-Calvet; Laura Martínez-Martínez; Jordi Diaz-Manera; Ricard Rojas-García; Elena Cortés-Vicente; Joana Turón; Carlos Casasnovas; Christian Homedes; Gerardo Gutiérrez-Gutiérrez; María Concepción Jimeno-Montero; José Berciano; Maria José Sedano-Tous; Tania García-Sobrino; Julio Pardo-Fernández; Celedonio Márquez-Infante; Iñigo Rojas-Marcos; Ivonne Jericó-Pascual; Eugenia Martínez-Hernández; Germán Morís de la Tassa; Cristina Domínguez-González; Cándido Juárez; Isabel Illa; Luis Querol
Journal:  J Neuroinflammation       Date:  2021-11-01       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.